SecurityEQC / Equity Commonwealth (294628102)
IndustryReal Estate Investment Trusts
Common Shares Outstanding124,427,966 shares (as of 2017-12-31)
Total Insiders15
Total Directors11
Total Officers5

Stock Insider Trading (from SEC Form 4)

Equity Commonwealth insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

EQC / Equity Commonwealth insiders include BROWN JEFFREY DOUGLAS, Corl James Scott Lozier James Lloyd Jr, Weinberg David S, STAR JAMES A, Shifrin Orrin S, MARKMAN ADAM SCOTT, SPECTOR GERALD A, ZELL SAMUEL, LINNEMAN PETER, Shea Kenneth, EDELMAN MARTIN L, and GLICKMAN EDWARD A, ROBERTSON MARY JANE, HELFAND DAVID, .

Insider Roster

Insider Dir Off 10% Shares Owned
Lozier James Lloyd Jr Director
X 14,784
MARKMAN ADAM SCOTT EVP, CFO & Treasurer
X 124,122
HELFAND DAVID President & CEO, Director
X X 539,129
BROWN JEFFREY DOUGLAS SVP & Chief Accounting Officer
X 5,866
ZELL SAMUEL Director
X 2,994,206
Weinberg David S EVP & Chief Operating Officer
X 148,614
Shifrin Orrin S EVP, Gen. Counsel & Secretary
X 115,458
EDELMAN MARTIN L Director
X 20,075
Corl James Scott Director
X 20,784
STAR JAMES A Director
X 303,608
SPECTOR GERALD A Director
X 20,075
Shea Kenneth Director
X
ROBERTSON MARY JANE Director
X 20,075
LINNEMAN PETER Director
X 20,784
GLICKMAN EDWARD A Director
X 20,784

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-03-27 4 Lozier James Lloyd Jr S D 30.01 -6,000 14,784 443,668
2018-03-22 4 MARKMAN ADAM SCOTT G I -900 124,122
2018-02-07 4 MARKMAN ADAM SCOTT F I 28.79 -7,736 125,022
2018-02-07 4 MARKMAN ADAM SCOTT A I 28.79 17,984 132,758
2018-02-07 4 Shifrin Orrin S F I 28.79 -8,977 115,458
2018-02-07 4 Shifrin Orrin S A I 28.79 13,834 124,435
2018-02-07 4 Weinberg David S F I 28.79 -7,985 148,614
2018-02-07 4 Weinberg David S A I 28.79 17,984 156,599
2018-02-07 4 ZELL SAMUEL A D 28.79 27,668 2,994,206
2018-02-07 4 BROWN JEFFREY DOUGLAS F D 28.79 -249 5,866
2018-02-07 4 BROWN JEFFREY DOUGLAS A D 28.79 423 6,115
2018-02-07 4 HELFAND DAVID F D 28.79 -22,337 539,129
2018-02-07 4 HELFAND DAVID A D 28.79 42,884 561,466
2018-01-29 4 BROWN JEFFREY DOUGLAS A D 637 5,692
2018-01-29 4 HELFAND DAVID A D 36,444 518,582
2018-01-29 4 MARKMAN ADAM SCOTT A I 15,283 114,774
2018-01-29 4 Shifrin Orrin S A I 11,756 110,601
2018-01-29 4 Weinberg David S A I 18,136 138,615
2018-01-29 4 ZELL SAMUEL A D 22,163 2,966,538
2017-11-08 4 BROWN JEFFREY DOUGLAS F D 30.48 -403 5,055
2017-11-08 4 BROWN JEFFREY DOUGLAS A D 30.48 1,191 5,458
2017-11-08 4 HELFAND DAVID F D 30.48 -26,808 482,138
2017-11-08 4 HELFAND DAVID A D 30.48 57,159 508,946
2017-11-08 4 MARKMAN ADAM SCOTT F I 30.48 -19,053 99,491
2017-11-08 4 MARKMAN ADAM SCOTT A I 30.48 19,053 108,427
2017-11-08 4 Shifrin Orrin S F I 30.48 -8,936 98,845
2017-11-08 4 Shifrin Orrin S A I 30.48 19,053 107,781
2017-11-08 4 Weinberg David S F I 30.48 -8,936 120,479
2017-11-08 4 Weinberg David S A I 30.48 19,053 129,415
2017-11-08 4 ZELL SAMUEL A D 30.48 83,357 2,944,375
2017-10-28 4 BROWN JEFFREY DOUGLAS F D 30.20 -275 4,267
2017-10-28 4 HELFAND DAVID F D 30.20 -18,282 451,787
2017-10-28 4 MARKMAN ADAM SCOTT F I 30.20 -4,730 89,374
2017-10-28 4 Shifrin Orrin S F I 30.20 -4,586 88,728
2017-10-28 4 Weinberg David S F I 30.20 -5,261 110,362
2017-06-20 4 GLICKMAN EDWARD A A D 3,156 20,784
2017-06-20 4 LINNEMAN PETER A D 3,156 20,784
2017-06-20 4 Lozier James Lloyd Jr A D 3,156 20,784
2017-06-20 4 ROBERTSON MARY JANE A D 3,156 20,075
2017-06-20 4 SPECTOR GERALD A A D 3,156 20,075
2017-06-20 4 STAR JAMES A A D 3,156 303,608
2017-06-20 4 Corl James Scott A D 3,156 20,784
2017-06-20 4 EDELMAN MARTIN L A I 3,156 20,075
2017-01-28 4 MARKMAN ADAM SCOTT F I 31.22 -1,440 94,104
2017-01-28 4 Shifrin Orrin S F I 31.22 -1,130 93,314
2017-01-28 4 BROWN JEFFREY DOUGLAS F D 31.22 -35 4,542
2017-01-28 4 HELFAND DAVID F D 31.22 -3,150 470,069
2017-01-24 4 Shifrin Orrin S A I 10,801 94,444
2017-01-24 4 BROWN JEFFREY DOUGLAS A D 524 4,577
2017-01-24 4 HELFAND DAVID A D 33,482 473,219
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

The Zacks Analyst Blog Highlights: First Trust Nasdaq, PowerShares S&P, SPDR S&P Oil, iShares U.S. Oil and PowerShares Dynamic Energy

2018-05-23 zacks
Chicago, IL – May 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include First Trust Nasdaq Oil & Gas ETF (FTXN - Free Report) , PowerShares S&P SmallCap Energy Fund (PSCE - Free Report) , SPDR S&P Oil & Gas Exploration & Production ETF (XOP - Free Report) , iShares U. (11-0)

The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

2018-05-23 zacks
Chicago, IL – May 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cisco (CSCO - Free Report) , Kraft Heinz (KHC - Free Report) ,Sinopec (SNP - Free Report) , Glaxo (GSK - Free Report) and Progressive (PGR - Free Report) . (25-0)

The Zacks Analyst Blog Highlights: Boeing, Caterpillar, Diodes, Texas Instruments and CNOOC

2018-05-23 zacks
Chicago, IL – May 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boeing (BA - Free Report) , Caterpillar Inc. (CAT - Free Report) , Diodes Inc. (DIOD - Free Report) , Texas Instruments Inc. (TXN - Free Report) and CNOOC Limited (CEO - Free Report) . (239-0)

The Zacks Analyst Blog Highlights: Oshkosh, Allison Transmission, Fox Factory, Ferrari and Lear

2018-05-23 zacks
Chicago, IL – May 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Oshkosh Corp. (OSK - Free Report) , Allison Transmission Holdings, Inc. (ALSN - Free Report) , Fox Factory Holding Corp. (FOXF - Free Report) , Ferrari N. (27-0)

Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth

2018-05-22 zacks
Chicago, IL – May 22, 2018 - Stocks in this week’s article VASCO Data Security International, Inc.’s (VDSI - Free Report) , Progenics Pharmaceuticals, Inc. (PGNX - Free Report) , Denny's Corporation (DENN - Free Report) , Columbus McKinnon Corp. (CMCO - Free Report) and Equity Commonwealth (EQC - Free Report) . (64-0)